BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12369972)

  • 21. New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease.
    Camps P; El Achab R ; Morral J; Muñoz-Torrero D; Badia A; Baños JE; Vivas NM; Barril X; Orozco M; Luque FJ
    J Med Chem; 2000 Nov; 43(24):4657-66. PubMed ID: 11101357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.
    Muñoz-Ruiz P; Rubio L; García-Palomero E; Dorronsoro I; del Monte-Millán M; Valenzuela R; Usán P; de Austria C; Bartolini M; Andrisano V; Bidon-Chanal A; Orozco M; Luque FJ; Medina M; Martínez A
    J Med Chem; 2005 Nov; 48(23):7223-33. PubMed ID: 16279781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biocomputational Screening of Natural Compounds against Acetylcholinesterase.
    Ahmad SS; Khan MB; Ahmad K; Lim JH; Shaikh S; Lee EJ; Choi I
    Molecules; 2021 Apr; 26(9):. PubMed ID: 33946559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of AChE: structure-activity relationship among conformational transition of Trp84 and biomolecular rate constant.
    Bertonati C; Marta M; Patamia M; Colella A; Pomponi M
    J Enzyme Inhib; 2000; 15(6):547-56. PubMed ID: 11140610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conformational flexibility in the peripheral site of Torpedo californica acetylcholinesterase revealed by the complex structure with a bifunctional inhibitor.
    Colletier JP; Sanson B; Nachon F; Gabellieri E; Fattorusso C; Campiani G; Weik M
    J Am Chem Soc; 2006 Apr; 128(14):4526-7. PubMed ID: 16594661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phthalimide-Derived N-Benzylpyridinium Halides Targeting Cholinesterases: Synthesis and Bioactivity of New Potential Anti-Alzheimer's Disease Agents.
    Saeedi M; Golipoor M; Mahdavi M; Moradi A; Nadri H; Emami S; Foroumadi A; Shafiee A
    Arch Pharm (Weinheim); 2016 Apr; 349(4):293-301. PubMed ID: 26898241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.
    Bolognesi ML; Cavalli A; Valgimigli L; Bartolini M; Rosini M; Andrisano V; Recanatini M; Melchiorre C
    J Med Chem; 2007 Dec; 50(26):6446-9. PubMed ID: 18047264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and structure-activity relationship of Huprine derivatives as human acetylcholinesterase inhibitors.
    Ronco C; Sorin G; Nachon F; Foucault R; Jean L; Romieu A; Renard PY
    Bioorg Med Chem; 2009 Jul; 17(13):4523-36. PubMed ID: 19473849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors.
    Huang L; Shi A; He F; Li X
    Bioorg Med Chem; 2010 Feb; 18(3):1244-51. PubMed ID: 20056426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of TRP84 in catalytic power and the specificity of AChE.
    Pomponi M; Sacchi S; Colella A; Patamia M; Marta M
    Biophys Chem; 1998 Jun; 72(3):239-46. PubMed ID: 9691268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of bivalent acetylcholinesterase inhibitors as potential therapeutic drugs for Alzheimer's disease.
    Du DM; Carlier PR
    Curr Pharm Des; 2004; 10(25):3141-56. PubMed ID: 15544504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lessons from functional analysis of AChE covalent and noncovalent inhibitors for design of AD therapeutic agents.
    Barak D; Ordentlich A; Kaplan D; Kronman C; Velan B; Shafferman A
    Chem Biol Interact; 2005 Dec; 157-158():219-26. PubMed ID: 16289124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of Acetylcholinesterase (AChE): A Potential Therapeutic Target to Treat Alzheimer's Disease.
    Li Y; Zhang XX; Jiang LJ; Yuan L; Cao TT; Li X; Dong L; Li Y; Yin SF
    Chem Biol Drug Des; 2015 Oct; 86(4):776-82. PubMed ID: 25736722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors.
    Savini L; Gaeta A; Fattorusso C; Catalanotti B; Campiani G; Chiasserini L; Pellerano C; Novellino E; McKissic D; Saxena A
    J Med Chem; 2003 Jan; 46(1):1-4. PubMed ID: 12502352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acetylcholinesterase complexed with bivalent ligands related to huperzine a: experimental evidence for species-dependent protein-ligand complementarity.
    Wong DM; Greenblatt HM; Dvir H; Carlier PR; Han YF; Pang YP; Silman I; Sussman JL
    J Am Chem Soc; 2003 Jan; 125(2):363-73. PubMed ID: 12517147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer's disease.
    Greenblatt HM; Dvir H; Silman I; Sussman JL
    J Mol Neurosci; 2003; 20(3):369-83. PubMed ID: 14501022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase.
    Kumar B; Kumar V; Prashar V; Saini S; Dwivedi AR; Bajaj B; Mehta D; Parkash J; Kumar V
    Eur J Med Chem; 2019 Sep; 177():221-234. PubMed ID: 31151057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and pharmacological evaluation of chalcone derivatives as acetylcholinesterase inhibitors.
    Liu HR; Liu XJ; Fan HQ; Tang JJ; Gao XH; Liu WK
    Bioorg Med Chem; 2014 Nov; 22(21):6124-33. PubMed ID: 25260958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease.
    Gurung AB; Aguan K; Mitra S; Bhattacharjee A
    J Biomol Struct Dyn; 2017 Jun; 35(8):1729-1742. PubMed ID: 27410776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation.
    Belluti F; Rampa A; Piazzi L; Bisi A; Gobbi S; Bartolini M; Andrisano V; Cavalli A; Recanatini M; Valenti P
    J Med Chem; 2005 Jun; 48(13):4444-56. PubMed ID: 15974596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.